Somatostatin and growth hormone regulation in cancer.
Somatostatin analogues are used clinically in a variety of pituitary and gastroenteropancreatic tumours. In addition, they may influence breast and prostate growth either directly through somatostatin receptors or indirectly through inhibition of growth hormone and prolactin release. Somatostatin analogues may interfere with EGF/TGF alpha-stimulated growth of these tumours and can suppress circulating levels of IGF-I in addition.